News and Announcements
Airbus integrates Mobilicom Limited’s (ASX: MOB) solution
- Published October 04, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Mobilicom to be integrated into global aerospace pioneer Airbus drone innovation platform.
- Mobilicom’s SkyHopper Pro will be combined with Airbus’ DJI drone commercial platform solution.
- This sale is a key step in expanding SkyHopper’s global presence.
Mobilicom Limited (Mobilicom) is pleased to announce that it has received an order from world-renowned global aerospace pioneer Airbus.
Mobilicom’s SkyHopper Pro will be combined with Airbus’ DJI drone commercial platform solution.
This platform is used to demonstrate Airbus’ mission operation algorithm and software in the commercial and homeland security drone space.
Mobilicom CEO, Oren Elkayam, believes this sale is a key step towards expanding Mobilicom and SkyHopper’s global presence.
Airbus is a global leader in aerospace and developing cutting-edge technology. The company has over 67 Billion Euro in revenues and over 129,000 employees on a global scale.
Airbus exhibited their innovation drone platform, integrated with SkyHopper by Mobilicom in France at Drones Paris Region Expo 2018.
About Mobilicom Limited (ASX: MOB)
Mobilicom designs, develops and markets solutions for mission critical and remote mobile private communication networks without the need for, or use of, any existing infrastructure. Mobilicom’s products and technology merge 4G communication with Mobile MESH technologies into a unified solution, with several product families that have been commercially deployed. Mobilicom’s SkyHopper entity targets the Professional, Commercial and Industrial UAV market.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
